The 2020 GIST award goes to Dr. Thomas Mühlenberg of the University of Duisburg-Essen
The GIST Group Switzerland, the support group for patients with gastrointestinal stromal tumor (GIST), has awarded its science prize for the eleventh time. The 2020 GIST prize, worth CHF 10,000, was awarded to Dr. Thomas Mühlenberg for this publication on:
KIT -Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors – TORC1/2 Inhibition as Salvage Strategy. Published in Molecular Cancer Therapeutics (2019). 18 (11), 1985 – 1996. Read the details of the study.
Overview of the study
The majority of patients with gastrointestinal stromal tumors (GIST) respond to treatment with specific KIT-inhibitors (e.g. imatinib), but develop resistance in the course of treatment. The development of effective salvage therapies hampered by the heterogeneity of the secondary mutations in KIT.
See the full press release here.
www.sakk.ch
www.gist.ch
